Vertex exec sells shares in 10b5-1 trade

Vertex Pharmaceuticals executive Ourania Tatsis reported two stock transactions.

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Ourania Tatsis reported two stock transactions. On February 11, 2026, she executed an open-market sale of 466 shares of common stock at $460.43 per share, leaving her with 51,436 directly owned shares.

On February 10, 2026, 2,140 shares were disposed of at $468.41 per share to cover tax obligations, a transaction coded as F. The sale was made under a company-approved Rule 10b5-1 trading plan that was entered into on August 21, 2025.

Insider Trade Summary

Net Seller: 466 shares

Net Sell 2 txns

Insider Tatsis Ourania

Role EVP, Chief Reg. & Quality Off.

Sold 466 shs ($215K)

Type	Security	Shares	Price	Value
Sale	Common Stock	466	$460.43	$215K
Exercise Price or Tax Liability	Common Stock	2,140	$468.41	$1.00M

Holdings After Transaction: Common Stock — 51,436 shares (Direct)

Footnotes (1)

1. F1. Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did VRTX executive Ourania Tatsis report?

Ourania Tatsis reported disposing of Vertex common stock in two transactions, totaling 2,606 shares. This included 2,140 shares for tax withholding at $468.41 and a 466-share open-market sale at $460.43, with all shares held and transacted directly.

How many VRTX shares did the executive sell in the open market?

She sold 466 shares of Vertex common stock in an open-market transaction at $460.43 per share. This sale was coded as “S” and left her with 51,436 directly owned shares of Vertex common stock after the transaction was completed.

What was the purpose of the 2,140 VRTX shares disposed of on February 10, 2026?

The 2,140 shares disposed of on February 10, 2026 were used to satisfy tax obligations. This transaction, coded “F,” reflects a tax-withholding disposition at $468.41 per share, rather than a discretionary open-market sale of Vertex common stock.

How many VRTX shares does the reporting person own after these transactions?

Following the reported transactions, Ourania Tatsis directly owns 51,436 shares of Vertex common stock. This figure reflects her holdings after both the 2,140-share tax-withholding disposition and the 466-share open-market sale were completed and recorded.

Was the VRTX insider sale made under a Rule 10b5-1 trading plan?

Yes, the sale was made under a company-approved Rule 10b5-1 trading plan. The filing notes that Dr. Tatsis’ plan was entered into on August 21, 2025, providing a pre-arranged framework for executing the reported stock sale.

What is the role of the insider involved in these VRTX transactions?

The reporting person, Ourania Tatsis, serves as Vertex’s EVP, Chief Regulatory and Quality Officer. Her Form 4 identifies her as an officer of the company, not a director or 10% owner, and all reported holdings are shown as directly owned.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 05:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tatsis Ourania

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Reg. & Quality Off.

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		F		2,140	D	$468.41	51,902	D
Common Stock	02/11/2026		S(1)		466	D	$460.43	51,436	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.